We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THS
851
DELISTED
Treehouse Foods
THS
| $395K | ﹤0.01% |
19,535
-10,973
| -36% | -$208K |
|
|
MNTN
852
MNTN Inc
MNTN
$707M
| $395K | ﹤0.01% |
+21,280
| New | +$484K |
|
853
First Business Financial Services
FBIZ
$574M
| $392K | ﹤0.01% |
7,648
-489
| -6% | -$25K |
|
854
Sutro Biopharma
STRO
$393M
| $387K | ﹤0.01% |
+44,575
| New | +$379K |
|
855
Ovintiv
OVV
$16.4B
| $381K | ﹤0.01% |
+9,433
| New | +$385K |
|
856
Royal Caribbean
RCL
$86.5B
| $379K | ﹤0.01% |
1,172
+31
| +3% | +$10.4K |
|
|
EWCZ
857
DELISTED
European Wax Center
EWCZ
| $379K | ﹤0.01% |
95,006
-23,517
| -20% | -$107K |
|
858
Stoke Therapeutics
STOK
$1.83B
| $354K | ﹤0.01% |
15,085
-108,397
| -88% | -$1.86M |
|
859
Clear Channel Outdoor Holdings
CCO
$1.23B
| $354K | ﹤0.01% |
+223,976
| New | +$279K |
|
860
EVI Industries
EVI
$194M
| $353K | ﹤0.01% |
+11,180
| New | +$292K |
|
861
Valhi
VHI
$386M
| $350K | ﹤0.01% |
22,200
-20,528
| -48% | -$344K |
|
862
MGP Ingredients
MGPI
$400M
| $343K | ﹤0.01% |
14,167
-712
| -5% | -$20.6K |
|
863
ARKO Corp
ARKO
$901M
| $340K | ﹤0.01% |
74,321
+54,451
| +274% | +$257K |
|
864
General Dynamics
GD
$106B
| $338K | ﹤0.01% |
+991
| New | +$312K |
|
865
PLAYSTUDIOS Inc
MYPS
$76.9M
| $335K | ﹤0.01% |
347,850
+216,829
| +165% | +$233K |
|
866
Moelis & Co
MC
$5.1B
| $333K | ﹤0.01% |
+4,675
| New | +$334K |
|
867
Resideo Technologies
REZI
$5.55B
| $332K | ﹤0.01% |
+7,682
| New | +$240K |
|
868
Groupon
GRPN
$1.07B
| $326K | ﹤0.01% |
13,955
-484
| -3% | -$13.9K |
|
869
Jakks Pacific
JAKK
$305M
| $324K | ﹤0.01% |
17,272
| – | – |
|
|
ORGN
870
DELISTED
Origin Materials
ORGN
| $323K | ﹤0.01% |
20,782
+18,592
| +849% | +$345K |
|
871
Lamb Weston
LW
$7.51B
| $323K | ﹤0.01% |
5,556
-19,652
| -78% | -$1.07M |
|
|
CTEV
872
Claritev Corp
CTEV
$386M
| $322K | ﹤0.01% |
6,074
-2,415
| -28% | -$133K |
|
873
Root
ROOT
$972M
| $320K | ﹤0.01% |
3,570
-152
| -4% | -$15.9K |
|
874
Corcept Therapeutics
CORT
$10.1B
| $318K | ﹤0.01% |
3,828
-451,623
| -99% | -$32.7M |
|
875
Pulmonx
LUNG
$52.8M
| $316K | ﹤0.01% |
194,778
-65,640
| -25% | -$137K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.